BMY, Hengrui $15B deal reported

Bristol Myers Squibb and Hengrui Pharma did not announce a new transaction on May 15. The companies said on May 12, 2026, that they had entered strategic collaboration and license agreements covering 13 early-stage programs in oncology, hematology and immunology. Bristol Myers described the package as a global strategic collaboration, while Hengrui disclosed the same agreements in investor materials and exchange filings. The reported headline value is up to $15.2 billion, not a flat $15 billion cash payment. Bristol Myers said it will pay Hengrui $600 million upfront, with up to $950 million due by 2028, and additional development, regulatory and sales milestone payments if programs advance. Bloomberg and STAT separately described the transaction as worth up to $15.2 billion. (investors.bms.com) The agreements matter because they combine asset licensing with broader research collaboration. Bristol Myers said the package spans 13 preclinical programs, and Hengrui said it retains options to co-develop select programs and to commercialize certain products in China under specified terms. The companies said the programs are intended to address unmet needs across cancer, blood disorders and immune diseases. (investors.bms.com) ### Did the companies actually announce this on May 15? May 12, 2026, is the date in Bristol Myers' press release, Hengrui's website posting and Hengrui's Hong Kong exchange filing. The company materials available publicly do not show a fresh May 15 announcement of a new Bristol Myers-Hengrui agreement. (investors.bms.com) Biotech and market commentary circulating on May 15 appears to be referring back to the May 12 disclosure. Bristol Myers' investor page also lists the Hengrui announcement under May 12. ### What exactly is Bristol Myers paying for? Bristol Myers said the agreements cover a portfolio of 13 early-stage programs and are designed to accelerate discovery and development globally. The company did not frame the arrangement as a single asset purchase. (investors.bms.com) (bms.com) Hengrui's filing said the programs involve innovative modalities and had not yet entered clinical research stages at signing. The filing also said Hengrui has the option to co-develop select programs and that commercialization rights in China are part of the structure for certain assets. ### Why does the $15.2 billion figure look larger than the cash changing hands now? (investors.bms.com) The $600 million upfront payment is the only amount Bristol Myers said it will pay immediately. Bristol Myers and Hengrui said the rest of the headline value depends on milestone payments tied to development, regulatory events and sales performance. (www1.hkexnews.hk) Bloomberg reported Bristol Myers could pay as much as $950 million by 2028, with the remainder dependent on later milestones across the portfolio. STAT likewise described the $15.2 billion figure as contingent on all included drugs hitting their milestones. ### Which disease areas and programs are included? Oncology, hematology and immunology are the three therapeutic areas named in the companies' statements. (investors.bms.com) Bristol Myers said the 13 programs are early stage, and Hengrui's filing said they had not yet entered clinical research at the time of signing. (bloomberg.com) Fierce Biotech reported Bristol Myers is using the collaboration to add Hengrui assets while tapping Chinese research and development capacity. That characterization came from Fierce's reporting on the deal terms and the companies' stated focus on speeding early innovation. ### What should readers watch next? Future disclosures will likely come from Bristol Myers investor materials, Hengrui exchange filings and any program-specific development updates. (investors.bms.com) The companies said milestone payments and co-development elections will depend on how the 13 programs progress. (fiercebiotech.com) July 30, 2026, is Bristol Myers' scheduled second-quarter results call, according to its investor page, and that is one potential date for additional management commentary on licensing costs or pipeline plans. Hengrui's next investor updates would also be expected through its public announcement channels and exchange filings. (bms.com) (investors.bms.com)